Versor Investments LP Has $2.42 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Versor Investments LP grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 119.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 12,304 shares of the medical research company’s stock after buying an additional 6,702 shares during the period. IQVIA makes up 0.4% of Versor Investments LP’s portfolio, making the stock its 27th largest position. Versor Investments LP’s holdings in IQVIA were worth $2,418,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. FMR LLC boosted its holdings in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after buying an additional 804,963 shares during the last quarter. JPMorgan Chase & Co. lifted its position in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Impax Asset Management Group plc boosted its position in shares of IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after acquiring an additional 157,809 shares in the last quarter. Nordea Investment Management AB raised its holdings in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of IQVIA by 3.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock worth $290,545,000 after acquiring an additional 39,772 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE:IQV opened at $190.77 on Thursday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The stock has a market cap of $33.59 billion, a P/E ratio of 25.44, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. The firm’s fifty day simple moving average is $199.40 and its 200 day simple moving average is $215.46.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Activity at IQVIA

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the transaction, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

IQV has been the subject of several research reports. Robert W. Baird dropped their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Truist Financial restated a “buy” rating and set a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Barclays lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $251.22.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.